Quick Answer
GoodRx Holdings, Inc. reported Stockholders Equity of $616.26 million for the year ending 2025.
- GoodRx Holdings, Inc. showed a decrease of -15.0% in Stockholders Equity from 2024 to 2025.
- This data is from GoodRx Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$1.15 billion | Q2 2019: -$1.13 billion | Q3 2019: -$1.10 billion | Q1 2020: -$1.06 billion | Q2 2020: -$1.03 billion | Q3 2020: $756.41 million | Q1 2021: $749.06 million | Q2 2021: $824.39 million | Q3 2021: $846.40 million | Q1 2022: $786.51 million | Q2 2022: $817.94 million | Q3 2022: $788.40 million | Q1 2023: $827.47 million | Q2 2023: $895.37 million | Q3 2023: $881.27 million | Q1 2024: $631.07 million | Q2 2024: $669.40 million | Q3 2024: $696.43 million | Q1 2025: $654.35 million | Q2 2025: $643.03 million | Q3 2025: $600.71 million.
- Over the full 9 years of available data (2017 to 2025), GoodRx Holdings, Inc.'s Stockholders Equity has grown by 2,040.8%.
- Historical annual values: Fiscal year 2025: $616.26 million | Fiscal year 2024: $724.66 million | Fiscal year 2023: $761.96 million | Fiscal year 2022: $814.83 million | Fiscal year 2021: $831.68 million | Fiscal year 2020: $711.36 million | Fiscal year 2019: -$1.09 billion | Fiscal year 2018: -$1.16 billion | Fiscal year 2017: -$31.75 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: